(Q37848654)

24 August 2017

1 reference

title

Can some patients avoid adjuvant chemotherapy for early-stage breast cancer? (English)

1 reference

24 August 2017

1 reference

Philippe L Bedard

1

0 references

Fátima Cardoso

object named as

Fatima Cardoso

series ordinal

2

0 references

language of work or name

English

0 references

publication date

1 March 2011

1 reference

Nature Reviews Clinical Oncology

24 August 2017

1 reference

24 August 2017

8

1 reference

24 August 2017

5

1 reference

24 August 2017

272-279

1 reference

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.

24 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Estimates of cancer incidence and mortality in Europe in 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Breast cancer assessment tools and optimizing adjuvant therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

The molecular portraits of breast tumors are conserved across microarray platforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Concordance among gene-expression-based predictors for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Triple-negative breast cancer: disease entity or title of convenience?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Gene-expression signatures in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Development of the 21-gene assay and its application in clinical practice and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

A gene-expression signature as a predictor of survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Clinical application of the 70-gene profile: the MINDACT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Genomic grade index is associated with response to chemotherapy in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

The decrease in breast-cancer incidence in 2003 in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Abstracts of the 30th Annual San Antonio Breast Cancer Symposium. December 13-16, 2007. San Antonio, Texas, USA

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Neoadjuvant chemotherapy: not the best option in estrogen receptor-positive, HER2-negative, invasive classical lobular carcinoma of the breast?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.19

Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21364525

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21364525

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21364525

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2011.19

1 reference

24 August 2017

1 reference

PubMed ID

21364525